Daix (France), Long Island City (New York, United States), May 20, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases with unmet medical need, today announced the results of the votes of its Combined Shareholders’ Meeting.
The Combined Shareholders' Meeting was held on Thursday May 19, 2022 at 2 p.m. at Hôtel Oceania Le Jura, 14 avenue Foch, 21000 Dijon (France), under the chairmanship of Mr. Frédéric Cren, Chairman and Chief Executive Officer and cofounder of Inventiva.
Mr. Frederic Cren proceeded to the usual formalities of the opening of the meeting, in particular to the constitution of the Bureau by appointing Mr. Pierre Broqua and Mr. Jean Volatier, as tellers, as well as Mr. Eric Duranson, as secretary of the Combined Shareholders' Meeting.
All the resolutions submitted to vote have been adopted by the shareholders, with the exception of the 30th resolution which would have empowered the Board of Directors to decide on share capital increases reserved for members of a company savings plan to be set up by the Company.
Pursuant to Article R. 22-10-14 IV. of the French Commercial Code, the Combined Shareholders’ Meeting approved, without modification, the compensation policy for corporate officers as presented in the 2021 Universal Registration Document (Part 3.5.1, pages 153 and seq.).
Information on the results of the votes is detailed below:
- Total number of shares composing the share capital: 40 873 551
- Total number of shares with voting rights: 40 802 918
| | Ordinary part | Extraordinary part | |||||
| Shareholders | Shares | Votes | Shareholders | Shares | Votes | ||
| Shareholders present | 1 | 50 | 50 | 1 | 50 | 50 | |
| Proxy to third parties | 0 | 0 | 0 | 0 | 0 | 0 | |
| Proxy to the Chairman | 119 | 122 188 | 153 298 | 119 | 122 188 | 153 298 | |
| Mail votes | 87 | 27 741 130 | 39 165 996 | 87 | 27 741 130 | 39 165 996 | |
| TOTAL | 207 | 27 863 368 | 39 319 344 | 207 | 27 863 368 | 39 319 344 | |
| Quorum | 68,287% | 68,287% | |||||
| Resolutions | State of adoption | Number of represented shares | Proportion of represented share capital (%) | Total number of votes cast | For | Against | Abstention | |||
| Number of votes | in % of votes cast | Number of votes | in % of votes cast | Number of votes | in % of the total voting rights | |||||
| Resolution 1 - OGM | Adopted | 27 863 368 | 68,169% | 39 319 199 | 39 318 749 | > 99,99% | 450 | < 0,01% | 145 | - |
| Resolution 2 - OGM | Adopted | 27 863 368 | 68,169% | 39 319 199 | 39 318 749 | > 99,99% | 450 | < 0,01% | 145 | - |
| Resolution 3 - OGM | Adopted | 27 863 368 | 68,169% | 39 319 199 | 39 318 749 | > 99,99% | 450 | < 0,01% | 145 | - |
| Resolution 4 - OGM | Adopted | 27 863 368 | 68,169% | 39 319 199 | 39 318 749 | > 99,99% | 450 | < 0,01% | 145 | - |
| Resolution 5 - OGM | Adopted | 27 863 368 | 68,169% | 39 319 199 | 39 318 749 | > 99,99% | 450 | < 0,01% | 145 | - |
| Resolution 6 - OGM | Adopted | 27 863 368 | 68,169% | 39 318 514 | 36 715 609 | 93,38% | 2 602 905 | 6,62% | 830 | - |
| Resolution 7 - OGM | Adopted | 27 863 368 | 68,169% | 39 318 514 | 36 715 574 | 93,38% | 2 602 940 | 6,62% | 830 | - |
| Resolution 8 - OGM | Adopted | 27 863 368 | 68,169% | 39 318 505 | 38 457 624 | 97,81% | 860 881 | 2,19% | 839 | - |
| Resolution 9 - OGM | Adopted | 27 863 368 | 68,169% | 38 699 850 | 38 597 606 | 99,74% | 102 244 | 0,26% | 619 494 | - |
| Resolution 10 - OGM | Adopted | 27 863 368 | 68,169% | 38 699 850 | 38 597 606 | 99,74% | 102 244 | 0,26% | 619 494 | - |
| Resolution 11 - OGM | Adopted | 27 863 368 | 68,169% | 39 318 514 | 38 674 432 | 98,36% | 644 082 | 1,64% | 830 | - |
| Resolution 12 - OGM | Adopted | 27 863 368 | 68,169% | 39 318 234 | 39 317 709 | > 99,99% | 525 | < 0,01% | 1 110 | - |
| Resolution 13 - OGM | Adopted | 27 863 368 | 68,169% | 39 317 594 | 38 598 105 | 98,17% | 719 489 | 1,83% | 1 750 | - |
| Resolution 14 - OGM | Adopted | 27 863 368 | 68,169% | 39 317 594 | 38 698 105 | 98,42% | 619 489 | 1,58% | 1 750 | - |
| Resolution 15 - EGM | Adopted | 27 863 368 | 68,169% | 39 317 594 | 37 954 167 | 96,53% | 1 363 427 | 3,47% | 1 750 | - |
| Resolution 16 - EGM | Adopted | 27 863 368 | 68,169% | 39 317 594 | 37 954 242 | 96,53% | 1 363 352 | 3,47% | 1 750 | - |
| Resolution 17 - EGM | Adopted | 27 863 368 | 68,169% | 39 317 534 | 39 317 009 | > 99,99% | 525 | < 0,01% | 1 810 | - |
| Resolution 18 - EGM | Adopted | 27 863 368 | 68,169% | 39 317 594 | 39 316 769 | > 99,99% | 825 | < 0,01% | 1 750 | - |
| Resolution 19 - EGM | Adopted | 27 863 368 | 68,169% | 39 319 179 | 37 080 780 | 94,31% | 2 238 399 | 5,69% | 165 | - |
| Resolution 20 - EGM | Adopted | 27 863 368 | 68,169% | 39 319 179 | 39 102 826 | 99,45% | 216 353 | 0,55% | 165 | - |
| Resolution 21 - EGM | Adopted | 27 863 368 | 68,169% | 39 319 179 | 36 438 322 | 92,67% | 2 880 857 | 7,33% | 165 | - |
| Resolution 22 - EGM | Adopted | 27 863 368 | 68,169% | 39 319 179 | 36 408 145 | 92,60% | 2 911 034 | 7,40% | 165 | - |
| Resolution 23 - EGM | Adopted | 27 863 368 | 68,169% | 39 291 157 | 36 408 141 | 92,66% | 2 883 016 | 7,34% | 28 187 | - |
| Resolution 24 - EGM | Adopted | 27 863 368 | 68,169% | 39 319 179 | 36 436 876 | 92,67% | 2 882 303 | 7,33% | 165 | - |
| Resolution 25 - EGM | Adopted | 27 863 368 | 68,169% | 39 291 157 | 36 407 845 | 92,66% | 2 883 312 | 7,34% | 28 187 | - |
| Resolution 26 - EGM | Adopted | 27 863 368 | 68,169% | 39 319 179 | 36 435 802 | 92,67% | 2 883 377 | 7,33% | 165 | - |
| Resolution 27 - EGM | Adopted | 27 863 368 | 68,169% | 39 319 179 | 36 436 856 | 92,67% | 2 882 323 | 7,33% | 165 | - |
| Resolution 28 - EGM | Adopted | 27 863 368 | 68,169% | 39 319 179 | 36 438 298 | 92,67% | 2 880 881 | 7,33% | 165 | - |
| Resolution 29 - EGM | Adopted | 27 863 368 | 68,169% | 39 319 179 | 36 438 298 | 92,67% | 2 880 881 | 7,33% | 165 | - |
| Resolution 30 - EGM | Rejected | 27 863 368 | 68,169% | 39 291 157 | 15 594 865 | 39,69% | 23 696 292 | 60,31% | 28 187 | - |
| Resolution 31 - EGM | Adopted | 27 863 368 | 68,169% | 39 319 179 | 39 318 434 | > 99,99% | 745 | < 0,01% | 165 | - |
| Resolution 32 - EGM | Adopted | 27 863 368 | 68,169% | 39 318 989 | 36 436 917 | 92,67% | 2 882 072 | 7,33% | 355 | - |
| Resolution 33 - EGM | Adopted | 27 863 368 | 68,169% | 39 291 177 | 36 409 030 | 92,66% | 2 882 147 | 7,34% | 28 167 | - |
| Resolution 34 - EGM | Adopted | 27 863 368 | 68,169% | 39 290 987 | 36 405 930 | 92,66% | 2 885 057 | 7,34% | 28 357 | - |
| Resolution 35 - EGM | Adopted | 27 863 368 | 68,169% | 39 319 199 | 39 318 749 | > 99,99% | 450 | < 0,01% | 145 | - |
| Resolution 36 - OGM | Adopted | 27 863 368 | 68,169% | 39 319 199 | 39 318 749 | > 99,99% | 450 | < 0,01% | 145 | - |
About Inventiva
Inventiva is a clinical-stage biopharmaceutical company focused on the research and development of oral small molecule therapies for the treatment of NASH and other diseases with significant unmet medical need. The Company benefits from a strong expertise and experience in the domain of compounds targeting nuclear receptors, transcription factors and epigenetic modulation. Inventiva’s lead product candidate, lanifibranor, is currently in a pivotal Phase III clinical trial, NATiV3, for the treatment of adult patients with NASH, a common and progressive chronic liver disease for which there are currently no approved therapies.
The Company has established a strategic collaboration with AbbVie in the area of autoimmune diseases that resulted in the discovery of the drug candidate cedirogant (ABBV-157), an oral RORg inverse agonist which is being evaluated in a Phase IIb clinical trial, led by AbbVie, in adult patients with moderate to severe chronic plaque psoriasis. Inventiva’s pipeline also includes odiparcil, a drug candidate for the treatment of adult mucopolysaccharidoses (MPS) VI patients. As part of Inventiva’s decision to focus clinical efforts on the development of lanifibranor, it suspended clinical efforts relating to odiparcil and is reviewing available options with respect to its potential further development. Inventiva is in the process of selecting an oncology development candidate for its Hippo signalling pathway program.
The Company has a scientific team of approximately 80 people with deep expertise in the fields of biology, medicinal and computational chemistry, pharmacokinetics and pharmacology, and clinical development. It owns an extensive library of approximately 240,000 pharmacologically relevant molecules, approximately 60% of which are proprietary, as well as a wholly‑owned research and development facility.
Inventiva is a public company listed on compartment C of the regulated market of Euronext Paris (ticker: IVA - ISIN: FR0013233012) and on the Nasdaq Global Market in the United States (ticker: IVA). www.inventivapharma.com.
Important Notice
This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release are forward-looking statements. These statements include, but are not limited to, forecasts and estimates with respect to Inventiva’s pipeline and preclinical and clinical development plans, future activities, expectations, plans, growth and prospects of Inventiva and the sufficiency of Inventiva’s cash resources and cash runway; and whether or to what extent Inventiva may use the share repurchase program and the objectives of any use of the share repurchase program or may undertake any transactions with respect to its securities as authorized by the resolutions approved at the Combined Shareholders' Meeting. Certain of these statements, forecasts and estimates can be recognized by the use of words such as, without limitation, “believes”, “anticipates”, “expects”, “intends”, “plans”, “seeks”, “estimates”, “may”, “will”, “would”, “could”, “might”, “should”, and “continue” and similar expressions. Such statements are not historical facts but rather are statements of future expectations and other forward-looking statements that are based on management's beliefs. These statements reflect such views and assumptions prevailing as of the date of the statements and involve known and unknown risks and uncertainties that could cause future results, performance or future events to differ materially from those expressed or implied in such statements. Future events are difficult to predict and may depend upon factors that are beyond Inventiva's control. There can be no guarantees with respect to pipeline product candidates that the clinical trial results will be available on their anticipated timeline, that future clinical trials will be initiated as anticipated, that product candidates will receive the necessary regulatory approvals, or that any of the anticipated milestones by Inventiva or its partners will be reached on their expected timeline, or at all. Actual results may turn out to be materially different from the anticipated future results, performance or achievements expressed or implied by such statements, forecasts and estimates, due to a number of factors, including that Inventiva is a clinical-stage company with no approved products and no historical product revenues, Inventiva has incurred significant losses since inception, Inventiva has a limited operating history and has never generated any revenue from product sales, Inventiva will require additional capital to finance its operations, Inventiva's future success is dependent on the successful clinical development, regulatory approval and subsequent commercialization of current and any future product candidates, preclinical studies or earlier clinical trials are not necessarily predictive of future results and the results of Inventiva's clinical trials may not support Inventiva's product candidate claims, Inventiva may encounter substantial delays in its clinical trials or Inventiva may fail to demonstrate safety and efficacy to the satisfaction of applicable regulatory authorities, enrollment and retention of patients in clinical trials is an expensive and time-consuming process and could be made more difficult or rendered impossible by multiple factors outside Inventiva's control, Inventiva's product candidates may cause adverse drug reactions or have other properties that could delay or prevent their regulatory approval, or limit their commercial potential, Inventiva faces substantial competition and Inventiva’s business, and preclinical studies and clinical development programs and timelines, its financial condition and results of operations could be materially and adversely affected by the current COVID-19 pandemic and geopolitical events, such as the conflict between Russia and Ukraine and related impacts and potential impacts on the initiation, enrolment and completion of Inventiva’s clinical trials on anticipated timeliness. Given these risks and uncertainties, no representations are made as to the accuracy or fairness of such forward-looking statements, forecasts and estimates. Furthermore, forward-looking statements, forecasts and estimates only speak as of the date of this press release. Readers are cautioned not to place undue reliance on any of these forward-looking statements.
Please refer to the Universal Registration Document for the year ended December 31, 2021 filed with the Autorité des Marchés Financiers on March 11, 2022 and the Annual Report on Form 20-F for the year ended December 31, 2021 filed with the Securities and Exchange Commission on March 11, 2022 for additional information in relation to such factors, risks and uncertainties.
All information in this press release is as of the date of the release. Except as required by law, Inventiva has no intention and is under no obligation to update or review the forward-looking statements referred to above.
Contacts
| Inventiva Pascaline Clerc VP of Global External Affairs media@inventivapharma.com +1 240 620 9175 | Brunswick Group Laurence Frost / Tristan Roquet Montegon / Aude Lepreux Media relations inventiva@brunswickgroup.com +33 1 53 96 83 83 | Westwicke, an ICR Company Patricia L. Bank Investor relations patti.bank@westwicke.com +1 415 513 1284 |
Attachment
